GROUPS JOIN CLC IN LETTER TO CONGRESS ENDORSING
November 27, 2001
The undersigned organizations, representing seniors, cancer patients, providers, and health care organizations, applaud the united and bipartisan response to the events of September 11. We join the rest of the nation in offering support to Congress and the Administration at this time of grief and recovery.
We understand that the energies of Congress must be directed to prompt action on measures to aid in the nation's healing from the recent terrorist attacks and that the Congressional agenda may be abbreviated to allow efforts to concentrate on recovery measures. However, if Congress chooses to consider a Medicare amendments package this year, we urge that you include a provision to expand current Medicare Part B coverage of anti-cancer drugs to oral anti-cancer agents for which there is no intravenous equivalent. House and Senate versions of the Access to Cancer Therapies Act (H.R. 1624 and S. 913), authorizing Medicare coverage of oral anti-cancer agents, enjoy broad bipartisan support and represent important incremental reform.
Medicare already covers the cost of most anti-cancer drugs because those drugs are administered by injection by providers. Since 1993, oral anti-cancer drugs with an injectable equivalent have also been covered by Medicare. Unfortunately, many of the most important oral anti-cancer agents would not be eligible for Medicare coverage because they have no intravenous equivalent.
To guarantee that seniors have access to new, more effective anti-cancer drugs, Medicare should pay for them. In the past, Medicare beneficiaries have been able to depend on the program for quality cancer care, and expanding the current system of coverage to include oral anti-cancer drugs will ensure that beneficiaries still have access to good cancer care. We believe that this approach would be a modest improvement to Medicare that Congress should consider this fall.
During the last year, you have heard from cancer advocates regarding this legislation, and they are now joined by a number of senior organizations in promoting this legislation to ensure that beneficiaries with cancer have access to all cancer treatment options. This is a responsible approach to enhancing Medicare benefits, and we urge you to consider it as a step toward more comprehensive reform in the future. We stand ready to provide you with additional information about promising new oral anti-cancer therapies and about how the Access to Cancer Therapies Act will help beneficiaries.
AFSCME Retiree Program
Cancer Leadership Council Alliance for Lung Cancer Advocacy, Support and Education American Cancer Society Association of American Cancer Institutes Cancer Care, Inc. Coalition of National Cancer Cooperative Groups, Inc. Colorectal Cancer Network Kidney Cancer Association The Leukemia & Lymphoma Society Lymphoma Research Foundation Multiple Myeloma Research Foundation National Coalition for Cancer Survivorship National Patient Advocate Foundation National Prostate Cancer Coalition Oncology Nursing Society Ovarian Cancer National Alliance Pancreatic Cancer Action Network Susan G. Komen Breast Cancer Foundation US TOO! International, Inc. The Wellness Community Y-ME National Breast Cancer Organization
Ellen Stovall, Executive
© 2001-2002 Cancer Leadership Council. All rights reserved.